Mirikizumab Improves Quality of Life in Crohn’s Disease Patients With and Without Prior Biologic Failure

A post hoc analysis of the phase 3 VIVID-1 trial (NCT03926130) presented at Advances in Inflammatory Bowel Diseases (AIBD), has revealed that mirikizumab, an anti-IL-23p19 antibody, significantly improves health-related quality of life (HRQoL) in patients with moderately-to-severely active Crohn’s disease (CD), regardless of prior biologic failure. 

The analysis included adult patients treated with mirikizumab or placebo. Prior biologic failure was defined as inadequate response, loss of response, or intolerance to at least one biologic therapy approved for CD. HRQoL outcomes were assessed using the Inflammatory Bowel Disease Questionnaire (IBDQ) and Work Productivity and Activity Impairment Questionnaire (WPAI):CD. 

At weeks 12 and 52, mirikizumab showed significantly greater improvements in IBDQ scores in both the bio-failed (Week 12: least squares mean [LSM] difference, 19.4; Week 52: LSM difference, 30.4; both P < .001) and not bio-failed (Week 12: LSM difference, 19.4; Week 52: LSM difference, 25.9; both P < .001) subgroups compared to placebo. Response and remission rates based on IBDQ scores were also higher for mirikizumab across both subgroups at all time points (all P < .001). 

Improvements in WPAI:CD scores were more pronounced in the bio-failed subgroup at Week 52 (LSM difference for activity impairment: -21.6, P < .001). In the not bio-failed subgroup, significant improvements were noted in presenteeism, work impairment, and activity impairment (LSM differences: -9.1 to -10.5; all P < .05) but not absenteeism. 

These findings highlight mirikizumab’s consistent ability to improve HRQoL in patients with moderate-to-severe CD, regardless of prior treatment history. The results reinforce its potential as a therapeutic option for patients across diverse clinical profiles. 

Reference
Lee S, Vermeire S, Ungaro RC. Mirikizumab improved the quality of life in patients with Crohn’s disease regardless of their previous biologic failure status: results from the phase 3 vivid-1 study. Presented at: Advances in Inflammatory Bowel Disease annual meeting; December 9-11, 2024. Orlando, Florida.